Lillia is a clinically proven, AI-powered platform that enables healthcare providers, insurers, corporations and public sector entities to manage chronic diseases effectively. Since 2020, Lillia has transformed 40,000 lives by enabling 20 institutional customers to support individuals in their diabetes and weight-related conditions across the GCC region and India. 85% of high-risk users saw significant reduction in blood sugar with Lillia, 80% of users lost 5% of body weight, while 35% of users reduced medication dependence in 3 months. With the development of the digital twin and with agentic AI solutions underway, Lillia is gearing up for expansion in MENA and South East Asia regions.
$1.7M sweet spot round size
2020
$1.7M
from 1 investors over 1 rounds
Lillia raised $1.7M on March 24, 2025
Investors: Qatar Research, Development and Innovation